HRT Financial’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21M Buy
1,243,317
+740,980
+148% +$10.4M 0.04% 459
2026
Q1
$6.44M Sell
502,337
-262,553
-34% -$3.34M 0.02% 848
2025
Q4
$6.88M Buy
+764,890
New +$10.5M 0.02% 625
2025
Q3
– Sell
-221,328
Closed -$2.08M – 3422
2025
Q2
$2.08M Buy
221,328
+133,175
+151% +$1.09M 0.01% 907
2025
Q1
$626K Buy
88,153
+55,758
+172% +$563K ﹤0.01% 1341
2024
Q4
$377K Buy
+32,395
New +$506K ﹤0.01% 1590
2021
Q4
– Sell
-8,913
Closed -$1.2M – 3788
2021
Q3
$1.2M Buy
+8,913
New +$1.35M 0.01% 1115

Other funds holding NTLA

HRT Financial's NTLA Position: Q2 2026 in Review

HRT Financial increased its Intellia Therapeutics (NTLA) stake by 148% in Q2 2026, buying an estimated $10.4M and bringing the position to 1,243,317 shares worth $21M. The position accounts for 0.04% of the portfolio, ranked #459.

HRT Financial first reported a position in NTLA in Q3 2021 and has held it in 7 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • HRT Financial held 1,243,317 shares of Intellia Therapeutics worth $21M as of Q2 2026.
  • HRT Financial bought 740,980 Intellia Therapeutics shares in Q2 2026, an estimated $10.4M.
  • Intellia Therapeutics made up 0.04% of HRT Financial's portfolio in Q2 2026, its #459 holding.
  • HRT Financial first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 7 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.